109 senior medical director indication lead jobs found

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. It is an exciting time of growth for argenx as we strive to achieve our VISION 2030. Vision 2030 includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets,...

Biogen About This Role Associate Director, Global Price & Access will help to develop and execute the global pricing, reimbursement and market access strategy for our future broader Nephrology portfolio. The Associate Director/Senior Manager, Global Price & Access (Pricing and Reimbursement) will be responsible for supporting the ongoing reimbursement/launch preparation in US, EU, and international markets. The individual will help to lead key global P&RS initiatives such as global pricing policy, pricing communications, value proposition and messages, detailed forecast assumptions, global price bands and launch sequence, support strategies with in-depth market research, environmental data & analogs. Additional focus will be to support LCM activities for nephrology, including providing input to new indication expansion business cases, Phase 3 trials, LTE and biomarker studies. Ability to collaborate with Cross-Functional colleagues, regional and US MAx...

Biogen Biogen's West Coast Hub, based in South San Francisco, is specifically focused on transforming the lives of patients with severe immune-mediated diseases by developing novel targeted therapies with outsized clinical impact, faster. To accomplish this, we are seeking top talent to join us on our journey. About This Role As the Head of Clinical Biomarkers, West Coast Hub (WCH), you will lead the Clinical Biomarkers function for our portfolio of investigational therapeutics spanning late stage research, early development, and late/registrational clinical development stages. This is a senior leadership role responsible for setting the strategic direction, oversight, and portfolio-wide advancement of the clinical biomarkers pillar for the WCH portfolio of therapeutics, covering multiple indications and therapeutic areas. Reporting directly to the Head of Biomarkers and Clinical Pharmacology, WCH, this role is pivotal in shaping and executing the biomarker vision for the...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

argenx Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases. We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients. The use of Real-World Evidence (RWE) to support decision making by regulators, payors & health technology assessment (HTA) authorities, health care providers (HCPs), patient organizations, and other stakeholders has accelerated. In...

Who we are Together, we’re on a mission to make good health more affordable and accessible, to help millions around the world enjoy healthier lives. It’s a mission that bonds our people across nearly 60 countries and a rich, diverse variety of nationalities and backgrounds. Working here means working with the world’s leading manufacturer of generic medicines, and the proud producer of many of the products on the World Health Organization’s Essential Medicines List. Today, at least 200 million people around the world take one of our medicines every single day. An amazing number, but we’re always looking for new ways to continue making a difference, and new people to make a difference with. The opportunity As Senior Director, Global Product Strategy - Emrusolmin & portfolio - you will define the long-term strategic vision and lead the global product strategy for Emrusolmin (and other global assets) - translating scientific innovation into long-term brand and business...

Who we are Together, we’re on a mission to make good health more affordable and accessible, to help millions around the world enjoy healthier lives. It’s a mission that bonds our people across nearly 60 countries and a rich, diverse variety of nationalities and backgrounds. Working here means working with the world’s leading manufacturer of generic medicines, and the proud producer of many of the products on the World Health Organization’s Essential Medicines List. Today, at least 200 million people around the world take one of our medicines every single day. An amazing number, but we’re always looking for new ways to continue making a difference, and new people to make a difference with. The opportunity As Senior Director, Global Product Strategy - Immunology Early Pipeline - you will define the long-term strategic vision, and lead the global product strategy for Teva’s early-stage immunology pipeline - translating scientific innovation into long-term brand and business...

Who we are Together, we’re on a mission to make good health more affordable and accessible, to help millions around the world enjoy healthier lives. It’s a mission that bonds our people across nearly 60 countries and a rich, diverse variety of nationalities and backgrounds. Working here means working with the world’s leading manufacturer of generic medicines, and the proud producer of many of the products on the World Health Organization’s Essential Medicines List. Today, at least 200 million people around the world take one of our medicines every single day. An amazing number, but we’re always looking for new ways to continue making a difference, and new people to make a difference with. The opportunity We are seeking an experienced Sr. Director, GCO Therapeutic Area Head to lead the strategic and operational global execution of all clinical trials within the Neuroscience TA. This leadership role oversees a team of approximately 15-20 professionals and is accountable...

Biogen Biogen's West Coast Hub, based in South San Francisco, is specifically focused on transforming the lives of patients with severe immune-mediated diseases by developing novel targeted therapies with outsized clinical impact, faster. To accomplish this, we are seeking top talent to join us on our journey. About This Role: As the Head of Biostatistics, West Coast Hub (WCH), you will lead the Biostatistics function for our portfolio of immune-mediated diseases, covering both early and late clinical development stages. This Senior Director level role will be instrumental in developing and overseeing strategic directions to ensure the scientific integrity and operational efficiency of biostatistical elements across multiple indications, driving innovations for Biogen WCH assets and development programs. This role is crucial for the biostatistics components of regulatory submissions, including NDA/BLA/MAA filings. Your leadership will foster a culture of inclusivity,...

Alkermes, Inc. This is a high impact position with great visibility across all levels of the Alkermes organization. This position will have critical responsibilities in the clinical department involved in the development of therapies for neurology and neuropsychiatric indications, including sleep disorders. Key trial related responsibilities include development of study protocols, medical review of clinical trial data and generation of clinical study reports. Additionally, the Medical Director will participate in internal strategy regarding future therapeutic priorities and interact externally with key global regulatory authorities, industry and scientific organizations, as well as external key thought leaders. This position will work cross-functionally to ensure projects are coordinated with partners from multiple departments within Alkermes including regulatory, preclinical research, clinical pharmacology, translational medicine, toxicology, CMC, new product planning, project...

Biogen About This Role The Fluid Biomarker group is seeking a highly motivated, experienced individual to join a dynamic team engaged in the implementation of biomarkers to support clinical therapeutic development. This role is required to oversee and support the development, implementation, and execution of biomarker strategies in support of programs in the Immunology portfolio. The successful candidate will have immunology expertise and a proven track record of strong leadership developing and delivering on biomarker strategies across all stages of drug development, with a particular focus on Phase 2 and beyond clinical development. Excellent strategic thinking, communication and collaboration skills are essential. What You'll Do In collaboration with other members of the biomarker team, develop and implement biomarker strategies for preclinical and clinical development programs. Provide guidance and direction to fluid members of the group focused on biomarker...